Obesity as a risk factor in venous thromboembolism, Am. J. Med, vol.118, pp.978-980, 2005. ,
Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery, Obes. Surg, vol.16, pp.1645-1655, 2006. ,
Thromboembolic events in bariatric surgery: a large multi-institutional referral center experience, Surg. Endosc, vol.29, pp.376-380, 2015. ,
Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis, Obes. Surg, vol.13, pp.819-825, 2003. ,
Pulmonary embolism complicating bariatric surgery: detailed analysis of a single institution's 24-year experience, J. Am. Coll. Surg, vol.203, pp.831-837, 2006. ,
Pulmonary embolism and deep venous thrombosis following bariatric surgery, Obes. Surg, vol.23, pp.663-668, 2013. ,
Effect of obesity on the pharmacokinetics of drugs in humans, Clin. Pharmacokinet, vol.49, pp.71-87, 2010. ,
Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin, Thromb. Res, vol.105, pp.201-204, 2002. ,
Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients, Br. J. Surg, vol.90, pp.547-548, 2003. ,
Prevention of venous thromboembolism in obesity, Expert Rev. Cardiovasc. Ther, vol.8, pp.1711-1721, 2010. ,
Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin, Obes. Surg, vol.18, pp.162-166, 2008. ,
Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery, Surg. Endosc, vol.22, pp.2392-2395, 2008. ,
Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity, Surg. Obes. Relat. Dis, vol.4, pp.625-631, 2008. ,
Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study), Thromb. Res, vol.124, pp.667-671, 2009. ,
Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels, Obes. Surg, vol.25, pp.628-634, 2015. ,
Prevention of venous thromboembolism in patients undergoing bariatric surgery, Vasc. Health Risk Manag, vol.11, pp.461-477, 2015. ,
Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by, Obesity, vol.21, pp.1-27, 2013. ,
, American Society for Metabolic Bariatric Surgery Clinical Issues Committee, ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients, Surg. Obes. Relat. Dis, vol.9, pp.493-497, 2013.
Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, Chest, vol.141, pp.227-277, 2012. ,
Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients, Thromb. Res, vol.125, pp.220-223, 2010. ,
Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery, Obes. Surg, vol.22, pp.47-51, 2012. ,
French society of anaesthesia and intensive care. Guidelines on perioperative venous thromboembolism prophylaxis. Update, Ann. Fr. Anesth. Reanim, vol.30, pp.947-951, 2011. ,
Recommendations for treatment of hyperlipidemia in adults: a joint statement of the Nutrition Committee and the Council on Arteriocslerosis, Circulation, vol.69, pp.1065-1090, 1984. ,
Quantification of lean bodyweight, Clin. Pharmacokinet, vol.44, pp.1051-1065, 2005. ,
The origin of the ideal body weight equations, Ann. Pharmacother, vol.34, pp.1066-1069, 2000. ,
The anti-factor xa range for low molecular weight heparin thromboprophylaxis, Hematol. Rep, vol.7, p.5844, 2015. ,
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients, J. Thromb. Haemost. JTH, vol.8, pp.202-204, 2010. ,
, Bariatric surgery worldwide 2013, vol.25, pp.1822-1832, 2015.
To what extent does posthospital discharge chemoprophylaxis prevent venous thromboembolism after bariatric surgery?: Results from a nationwide cohort of more than 110,000 patients, Ann. Surg, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01761872
Enoxaparin venous thromboembolism prophylaxis in bariatric surgery: a best evidence topic, Int. J. Surg. Lond. Engl, vol.23, pp.52-56, 2015. ,
Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis, Thromb. Res, vol.133, pp.682-687, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01026433
Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin, J. Nutr. Health Aging, vol.16, pp.647-652, 2012. ,
What is the best size descriptor to use for pharmacokinetic studies in the obese?, Br. J. Clin. Pharmacol, vol.58, pp.119-133, 2004. ,
Lean-scaled weight: a proposed weight scalar to calculate drug doses for obese patients, Can. J. Anaesth, vol.60, pp.214-215, 2013. ,
Anti-Xa levels 4 h after subcutaneous administration of 5,700 IU nadroparin strongly correlate with lean body weight in morbidly obese patients, Obes. Surg, 2012. ,
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint, Eur. J. Clin. Pharmacol, vol.71, pp.25-34, 2015. ,
Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review, Can. J. Hosp. Pharm, vol.68, pp.33-47, 2015. ,